Oncology News | pharmaphorum

News

Jeremy Skillington, Poolbeg's chief executive

Poolbeg expects first data for CRS drug in the summer

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

News

Lilly trumpets strong result for Jaypirca in CLL at EHA

New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

AZ's Truqap and Roche assay cleared for PTEN prostate cancer

AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.

News

Pushy NHS chatbots 'can put patients off screening'

Amid the push to digitise the UK health service, a study has sounded a note of caution about entrusting important patient appointments to chatbots.

News

Cancer biotech Parabilis books record IPO, raising $670m

Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.

Poolbeg expects first data for CRS drug in the summer

Lilly trumpets strong result for Jaypirca in CLL at EHA

Data could move J&J's Talvey earlier in myeloma therapy

AZ's Truqap and Roche assay cleared for PTEN prostate cancer

Pushy NHS chatbots 'can put patients off screening'

Cancer biotech Parabilis books record IPO, raising $670m

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks